Session: Pathogenetic Mechanisms of Abnormalities of Glucose, Insulin, Lipid, and Mitochondrial Metabolism

Home

Session 99 Poster
Pathogenetic Mechanisms of Abnormalities of Glucose, Insulin, Lipid, and Mitochondrial Metabolism
Monday, 1:30 - 3:30 pm
Poster Hall

<%SessionModeratorsLabel%>	<%M1Name%> <%M1Aff%> <%ModAnd%> <%M2Name%> <%M2Aff%>
701	Impaired Glucose Metabolism and Antiretroviral Use among HIV-infected Women A A Howard^1,2, M Floris-Moore^1,2, J Arnsten^1,2, N Santoro^1,2, and E E Schoenbaum^1,2 ¹Montefiore Med. Ctr. and ²Albert Einstein Coll. of Med., Bronx, NY, USA*
702	The Effect of Atazanavir vs Lopinavir/ritonavir on Insulin-stimulated Glucose Disposal Rate in Healthy Subjects M Noor*¹, D Grasela¹, R Parker¹, U Chaudhari¹, H Uderman¹, A Currie¹, S Agarwala¹, C Grunfeld², M Giordano³, S Hodder⁴, F Fiedorek¹, and E O'Mara¹ ¹Bristol-Myers Squibb Pharm. Res. Inst., Princeton, NJ, USA; ²Univ. of California, San Francisco, USA; ³Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, NJ, USA; and ⁴Bristol-Myers Squibb, Virology Med. Affairs, Plainsboro, NJ, USA
703	Derangements in Lipid and Glucose Kinetics in Patients with HIV Infection and Metabolic Complications D N Reeds, B W Patterson, W T Cade, W G Powderly, K E Yarasheski, and S Klein Washington Univ. Sch. of Med., St. Louis, MO, USA*
704	Insulin Resistance and Apolipoprotein B Kinetics: A Comparison of Protease Inhibitor-, Efavirenz-, or Nevirapine-containing Antiretroviral Regimens M Shahmanesh¹, S Das¹, M Stolinski², W Jefferson², N Jackson², G Gilleran¹, R Cramb¹, and M Umpleby² ¹Univ. Hosp. Birmingham, Natl. Hlth. Svc. Trust, UK and ²Guy’s Kings Coll. and St Thomas’ Hospitals’ Schs. of Med., London, UK*
705	HIV Protease Inhibitors Increase Adiponectin Levels in HIV-negative Men Independent of Induction of Insulin Resistance G A Lee¹, D D Mafong², M A Noor^1,3, J C Lo¹, K Mulligan¹, J-M Schwarz^1,4, M Schambelan¹, and C Grunfeld¹ ¹Univ. of California, San Francisco, USA; ²Univ. Hospitals of Cleveland, OH, USA; ³currently at Bristol-Myers Squibb Co., Princeton, NJ, USA; and ⁴Univ. of California, Berkeley, USA*
706	Differential Effects of HIV Protease Inhibitors on Proteasome, Gene Expression, and Lipogenesis Provide a Mechanism for PI-associated Dyslipidemia and Atazanavir's Favorable Lipid Profile R A Parker, S Wang, R Mulvey, C Elosua, W Fenderson, W-P Yang, and O P Flint Bristol-Myers Squibb Pharm. Res. Inst., Princeton, NJ, USA*
707	Effect of NRTI and PI on TNF-alpha and Adiponectin mRNA expression in Isolated Subcutaneous and Omental Mature Human Adipocytes S P Jones, C J Waitt, D J Back, and M Pirmohamed Univ. of Liverpool, UK*
708	Ritonavir Accumulates into Cultured Human Adipocytes and Alters Insulin Resistance Related Adipocytokines Levels C Vernochet¹, S Azoulay², D Duval², G Guedj², H Groux³, H Vidal⁴, G Ailhaud¹, and C Dani¹ ¹CNRS UMR6543, Nice, France; ²CNRS UMR6001, Nice, France; ³INSERM U576, Nice, France; and ⁴INSERM U449, Lyon, France*
709	Longitudinal Assessment of Mitochondrial DNA and RNA in PBMC in a Randomized Comparative Trial of NRTI-sparing and NRTI-containing Antiretroviral Combination Therapy M Casula*¹, G Weverling², M de Baar³, F Wit¹, M Stek⁴, J Lange^1,2, and P Reiss² ¹Intl. Antiviral Therapy Evaluation Ctr., Amsterdam, The Netherlands; ²Academic Med. Ctr., Amsterdam, The Netherlands; ³Primagen, Amsterdam, The Netherlands; and ⁴Merck & Co. Inc., Whitehouse Station, NJ, USA
710	Mitochondrial DNA Depletion in Adipose Tissues but Not PBMC Correlate with Lipoatrophy in HIV-infected Patients M Gerschenson¹, B Shiramizu¹, D Tran¹, C O O'Callaghan², D E LiButti¹, and C M Shikuma¹ ¹Univ. of Hawaii, Honolulu, USA and ²Queen's Univ., Kingston, Ontario, Canada*
711	Partial Improvement of Mitochondrial Dysfunction 48 weeks after Replacement of Stavudine with either Abacavir or Zidovudine G McComsey¹, C Hoppel¹, V Williams², T Lancaster², J Hernandez², and L Ross² ¹Case Western Reserve Univ., Cleveland, OH, USA and ²GlaxoSmithKline, Research Triangle Park, NC, USA*